EGFR and hematologic disorder: 90Y is one of the very promising radionuclides used for radioimmunotherapy of hematologic malignancies and solid tumors [19], [20], [21] Such radionuclide therapy outcomes will be independent of mutations in HER1 or KRAS domains and therefore overcome the existing limitations of conventional HER1-targeted therapy.